As one of the two pathological hallmarks of AD, the development of tau-specific tracers took place during the early years of the Aβ-specific tracer discoveries and thrived considerably after the revelation of Aβ’s accumulation in non-AD dementia and mild cognitive decline patients. This evidence concerns the gene MAPT and Alzheimer disease.